Biorithm announced it has closed a $3.5 million Series A funding round to support its personalized and connected maternity care technology.
Adaptive Capital Partners and SEEDS Capital jointly led the funding round. Cambridge, Massachusetts-based Biorhythm plans to use the funding to fuel expansion in Southeast Asia and the United States, and will also use the cash injection to advance its Femom obstetric remote monitoring solution. Planning. This includes completing clinical studies in support of FDA 510(k) premarket filings.
Biorithm aims to eliminate preventable pregnancy complications through protocol-based remote monitoring of maternal and fetal biometrics. Femom is a patient-friendly product that facilitates patient monitoring and accessible, personalized guidance. This enables seamless integration of predictive analytics to help clinicians identify early signs of complications.
The company has already completed clinical trials in Singapore and the UK and is now planning to expand into more priority markets.
“We are deeply committed to improving the health of pregnant women and eliminating preventable complications. Socioeconomic factors and the limitations of current surveillance technologies make it difficult to maintain maternal care in many parts of the world. is collapsing and we are working hard with other regions to resolve this issue,” said Amrish Nar, Founder and CEO of BIorithm. Ta. . “The investment we have received is a testament to our mission at Biorhythm and a future where every pregnant woman has access to health care that is not only preventive, but deeply relevant to her unique journey.”
